Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. The… Read more
Shanghai RAAS Blood Products Co Ltd Class A (002252) - Net Assets
Latest net assets as of September 2025: CN¥32.58 Billion CNY
Based on the latest financial reports, Shanghai RAAS Blood Products Co Ltd Class A (002252) has net assets worth CN¥32.58 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥38.02 Billion) and total liabilities (CN¥5.44 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥32.58 Billion |
| % of Total Assets | 85.7% |
| Annual Growth Rate | 29.6% |
| 5-Year Change | 27.1% |
| 10-Year Change | 198.17% |
| Growth Volatility | 165.9 |
Shanghai RAAS Blood Products Co Ltd Class A - Net Assets Trend (2005–2024)
This chart illustrates how Shanghai RAAS Blood Products Co Ltd Class A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai RAAS Blood Products Co Ltd Class A (2005–2024)
The table below shows the annual net assets of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥31.94 Billion | +7.73% |
| 2023-12-31 | CN¥29.65 Billion | +2.90% |
| 2022-12-31 | CN¥28.81 Billion | +11.23% |
| 2021-12-31 | CN¥25.90 Billion | +3.08% |
| 2020-12-31 | CN¥25.13 Billion | +118.69% |
| 2019-12-31 | CN¥11.49 Billion | +5.50% |
| 2018-12-31 | CN¥10.89 Billion | -12.72% |
| 2017-12-31 | CN¥12.48 Billion | +6.39% |
| 2016-12-31 | CN¥11.73 Billion | +9.50% |
| 2015-12-31 | CN¥10.71 Billion | +24.21% |
| 2014-12-31 | CN¥8.62 Billion | +682.76% |
| 2013-12-31 | CN¥1.10 Billion | +8.07% |
| 2012-12-31 | CN¥1.02 Billion | +9.94% |
| 2011-12-31 | CN¥927.27 Million | +11.56% |
| 2010-12-31 | CN¥831.21 Million | +8.89% |
| 2009-12-31 | CN¥763.33 Million | +1.14% |
| 2008-12-31 | CN¥754.76 Million | +343.95% |
| 2007-12-31 | CN¥170.01 Million | +8.44% |
| 2006-12-31 | CN¥156.77 Million | -32.34% |
| 2005-12-31 | CN¥231.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai RAAS Blood Products Co Ltd Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6978.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥9.92 Billion | 31.08% |
| Common Stock | CN¥6.64 Billion | 20.79% |
| Other Components | CN¥15.37 Billion | 48.13% |
| Total Equity | CN¥31.93 Billion | 100.00% |
Shanghai RAAS Blood Products Co Ltd Class A Competitors by Market Cap
The table below lists competitors of Shanghai RAAS Blood Products Co Ltd Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
0IHQ
LSE:0IHQ
|
$3.77 Billion |
|
Guangzhou Haige Communications Group Incorporated Co
SHE:002465
|
$3.77 Billion |
|
Petrobras Distribuidora S.A
PINK:PETRY
|
$3.77 Billion |
|
Havells India Limited
NSE:HAVELLS
|
$3.77 Billion |
|
Zhongfu Shenying Carbon Fiber Co. Ltd. A
SHG:688295
|
$3.76 Billion |
|
MRF Limited
NSE:MRF
|
$3.76 Billion |
|
Lynas Rare Earths Ltd
PINK:LYSCF
|
$3.76 Billion |
|
Omv Petrom S.A
RO:SNP
|
$3.76 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai RAAS Blood Products Co Ltd Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 29,633,949,195 to 31,926,258,696, a change of 2,292,309,501 (7.7%).
- Net income of 2,193,293,374 contributed positively to equity growth.
- Dividend payments of 439,854,694 reduced retained earnings.
- Other factors increased equity by 538,870,822.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥2.19 Billion | +6.87% |
| Dividends Paid | CN¥439.85 Million | -1.38% |
| Other Changes | CN¥538.87 Million | +1.69% |
| Total Change | CN¥- | 7.74% |
Book Value vs Market Value Analysis
This analysis compares Shanghai RAAS Blood Products Co Ltd Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.29x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 25.67x to 1.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | CN¥0.24 | CN¥6.21 | x |
| 2006-12-31 | CN¥0.16 | CN¥6.21 | x |
| 2007-12-31 | CN¥0.06 | CN¥6.21 | x |
| 2008-12-31 | CN¥0.24 | CN¥6.21 | x |
| 2009-12-31 | CN¥0.22 | CN¥6.21 | x |
| 2010-12-31 | CN¥0.23 | CN¥6.21 | x |
| 2011-12-31 | CN¥0.26 | CN¥6.21 | x |
| 2012-12-31 | CN¥0.28 | CN¥6.21 | x |
| 2013-12-31 | CN¥0.29 | CN¥6.21 | x |
| 2014-12-31 | CN¥2.06 | CN¥6.21 | x |
| 2015-12-31 | CN¥2.15 | CN¥6.21 | x |
| 2016-12-31 | CN¥2.40 | CN¥6.21 | x |
| 2017-12-31 | CN¥2.53 | CN¥6.21 | x |
| 2018-12-31 | CN¥2.22 | CN¥6.21 | x |
| 2019-12-31 | CN¥2.27 | CN¥6.21 | x |
| 2020-12-31 | CN¥3.73 | CN¥6.21 | x |
| 2021-12-31 | CN¥3.84 | CN¥6.21 | x |
| 2022-12-31 | CN¥4.28 | CN¥6.21 | x |
| 2023-12-31 | CN¥4.50 | CN¥6.21 | x |
| 2024-12-31 | CN¥4.80 | CN¥6.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai RAAS Blood Products Co Ltd Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.87%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.82%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.05x
- Recent ROE (6.87%) is below the historical average (13.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 22.14% | 16.90% | 0.91x | 1.44x | CN¥28.10 Million |
| 2006 | 32.41% | 18.20% | 0.86x | 2.08x | CN¥35.06 Million |
| 2007 | 48.66% | 26.38% | 1.01x | 1.82x | CN¥64.96 Million |
| 2008 | 13.95% | 33.82% | 0.37x | 1.11x | CN¥29.67 Million |
| 2009 | 17.88% | 35.01% | 0.47x | 1.09x | CN¥59.81 Million |
| 2010 | 22.51% | 38.38% | 0.52x | 1.13x | CN¥103.09 Million |
| 2011 | 21.91% | 35.82% | 0.55x | 1.10x | CN¥108.89 Million |
| 2012 | 22.42% | 33.96% | 0.55x | 1.20x | CN¥124.65 Million |
| 2013 | 13.23% | 28.97% | 0.32x | 1.45x | CN¥35.07 Million |
| 2014 | 5.93% | 38.71% | 0.14x | 1.09x | CN¥-350.12 Million |
| 2015 | 13.53% | 71.64% | 0.17x | 1.08x | CN¥376.57 Million |
| 2016 | 13.78% | 69.35% | 0.18x | 1.13x | CN¥442.28 Million |
| 2017 | 6.71% | 43.36% | 0.13x | 1.16x | CN¥-410.35 Million |
| 2018 | -13.96% | -84.16% | 0.16x | 1.05x | CN¥-2.61 Billion |
| 2019 | 5.30% | 23.52% | 0.22x | 1.03x | CN¥-539.98 Million |
| 2020 | 5.27% | 47.93% | 0.11x | 1.01x | CN¥-1.19 Billion |
| 2021 | 5.00% | 30.19% | 0.16x | 1.05x | CN¥-1.30 Billion |
| 2022 | 6.52% | 28.63% | 0.22x | 1.06x | CN¥-1.00 Billion |
| 2023 | 6.00% | 22.34% | 0.25x | 1.08x | CN¥-1.18 Billion |
| 2024 | 6.87% | 26.82% | 0.24x | 1.05x | CN¥-999.33 Million |
Industry Comparison
This section compares Shanghai RAAS Blood Products Co Ltd Class A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,066,877,026
- Average return on equity (ROE) among peers: 13.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | CN¥32.58 Billion | 22.14% | 0.17x | $3.76 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |